1-3 of 3
Cristina Mosca
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SETD2 deficiency in chronic myeloid leukemia (CML) contributes to tyrosine kinase inhibitor (TKI) resistance and disease acceleration by enhancing genetic instability and rewiring cellular metabolism and might be a novel biomarker of high risk disease since diagnosis

Free
Manuela Mancini, Lucia Romagnoli, Sara De Santis, Samantha Bruno, Cristina Mosca, Andrea Oldani, Alessandra Tagliavia, Alessandra Merlotti, Daniel Remondini, Erika Esposito, Jessica Fiori, Fausto Castagnetti, Miriam Iezza, Roberta Restuccia, Vanessa Bagnis, Alessandra Iurlo, Daniele Cattaneo, Marco Cerrano, Valentina Giai, Sara Galimberti, Pier Luigi Zinzani, Simona Soverini
Journal: Blood
Blood (2025) 146 (Supplement 1): 5557.
https://doi.org/10.1182/blood-2025-5557
Published: 2025
Journal Articles

Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association

Free
Simona Soverini, Cecilia Monaldi, Sara De Santis, Manuela Mancini, Francesco Albano, Luisa Anelli, Loredana Bruno, Ignazio Brusca, Grazia Fazio, Lilia Maria Corral Abascal, Francesca Guerrini, Clara Bono, Giovanni Iaquinta, Paola Grammatico, Elisabetta Novella, Omar Perbellini, Orietta Spinelli, Silvia Salmoiraghi, Stefano Baldoni, Alessia Persico, Giuseppa De Luca, Calogero Lauricella, Giovanna Piras, Angelo D. Palmas, Samantha Bruno, Cristina Mosca, Chiara Sartor, Cristina Papayannidis, Paola Guglielmelli, Alessandro M. Vannucchi, Patrizia Bonadonna, Francesco Mannelli, Nicholas C. P. Cross, Michele Cavo, Roberta Zanotti, Chiara Elena
Journal: Blood
Blood (2024) 144 (Supplement 1): 7640.
https://doi.org/10.1182/blood-2024-202485
Published: 2024
Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Free
Simona Soverini, Sara De Santis, Cecilia Monaldi, Manuela Mancini, Valentina Giai, Marco Cerrano, Isabella Capodanno, Massimiliano Bonifacio, Elisabetta Abruzzese, Alessandra Iurlo, Fausto Castagnetti, Rosaria Sancetta, Luciano Levato, Carmen Fava, Mario Tiribelli, Francesco Cavazzini, Maria Cristina Miggiano, Niccolò Bolli, Agostino Tafuri, Alessandro Lucchesi, Daniele Vallisa, Monia Lunghi, Caterina Musolino, Samantha Bruno, Cristina Mosca, Mauro Ciriello, Giovanni Marsili, Alfonso Piciocchi, Paola Fazi, Michele Cavo, Jeroen J.W.M. Janssen, Peter E. Westerweel, Fabrizio Pane
Journal: Blood
Blood (2024) 144 (Supplement 1): 3158.
https://doi.org/10.1182/blood-2024-205465
Published: 2024